KR102465491B1 - 항 hla-g 특이적 항체 - Google Patents

항 hla-g 특이적 항체 Download PDF

Info

Publication number
KR102465491B1
KR102465491B1 KR1020187037215A KR20187037215A KR102465491B1 KR 102465491 B1 KR102465491 B1 KR 102465491B1 KR 1020187037215 A KR1020187037215 A KR 1020187037215A KR 20187037215 A KR20187037215 A KR 20187037215A KR 102465491 B1 KR102465491 B1 KR 102465491B1
Authority
KR
South Korea
Prior art keywords
hla
antibody
ser
thr
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187037215A
Other languages
English (en)
Korean (ko)
Other versions
KR20190044589A (ko
Inventor
드무아옌 피에르 랑그라드
티에리 위에
줄리앙 꼬마르땡
마리아 루스또
마리아 웨흐베
Original Assignee
잉벡띠스 에스에이에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 잉벡띠스 에스에이에스 filed Critical 잉벡띠스 에스에이에스
Publication of KR20190044589A publication Critical patent/KR20190044589A/ko
Application granted granted Critical
Publication of KR102465491B1 publication Critical patent/KR102465491B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/575—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020187037215A 2016-06-03 2017-06-02 항 hla-g 특이적 항체 Active KR102465491B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16305650.0 2016-06-03
EP16305650 2016-06-03
PCT/EP2017/063503 WO2017207775A1 (en) 2016-06-03 2017-06-02 Anti hla-g specific antibodies

Publications (2)

Publication Number Publication Date
KR20190044589A KR20190044589A (ko) 2019-04-30
KR102465491B1 true KR102465491B1 (ko) 2022-11-11

Family

ID=56413601

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187037215A Active KR102465491B1 (ko) 2016-06-03 2017-06-02 항 hla-g 특이적 항체

Country Status (15)

Country Link
US (5) US20190233520A1 (enExample)
EP (1) EP3464364A1 (enExample)
JP (2) JP7034950B2 (enExample)
KR (1) KR102465491B1 (enExample)
CN (2) CN109563169B (enExample)
AU (1) AU2017272875B2 (enExample)
BR (1) BR112018074847A2 (enExample)
CA (1) CA3025681A1 (enExample)
EA (1) EA201892793A1 (enExample)
IL (1) IL263266B2 (enExample)
MX (1) MX2018014979A (enExample)
NZ (2) NZ788807A (enExample)
SG (2) SG10202107205VA (enExample)
WO (1) WO2017207775A1 (enExample)
ZA (1) ZA201808332B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2730588A1 (en) 2012-11-12 2014-05-14 Intelectys Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof
NZ788807A (en) 2016-06-03 2025-11-28 Invectys Anti hla-g specific antibodies
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
CN110573522B (zh) 2017-01-05 2023-09-19 卡尔医学有限公司 SIRPα-41BBL融合蛋白及其使用方法
RU2769513C2 (ru) 2017-01-05 2022-04-01 Кахр Медикал Лтд. Слитый белок pd1-4-1bbl и способы его применения
US11566060B2 (en) 2017-01-05 2023-01-31 Kahr Medical Ltd. PD1-CD70 fusion protein and methods of use thereof
AR115052A1 (es) 2018-04-18 2020-11-25 Hoffmann La Roche Anticuerpos multiespecíficos y utilización de los mismos
AR114789A1 (es) * 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
TW202428604A (zh) 2018-07-09 2024-07-16 美商戊瑞治療有限公司 結合至ilt4的抗體
MX2021000047A (es) 2018-07-11 2021-05-12 Kahr Medical Ltd Proteina de fusion variante pd1-4-1bbl y procedimientos de uso de la misma.
KR20210044220A (ko) 2018-07-11 2021-04-22 카 메디컬 리미티드 SIRPalpha-4-1BBL 변이체 융합 단백질 및 이의 사용 방법
EP3827020A1 (en) 2018-07-24 2021-06-02 Amgen Inc. Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors
EP3843778A1 (en) 2018-08-31 2021-07-07 Invectys Sa Chimeric antigen receptors against multiple hla-g isoforms
CA3114407A1 (en) 2018-09-27 2020-04-02 Tizona Therapeutics Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
CN114981304B (zh) * 2019-08-14 2024-08-20 安托拉诊疗公司 与lrp6蛋白结合的抗体及使用方法
AU2020369092A1 (en) * 2019-10-25 2022-05-12 Intellexon Gmbh HLA-H, HLA-J, HLA-L, HLA-V and HLA-Y as therapeutic and diagnostic targets
CN113045656B (zh) * 2020-07-27 2022-03-08 台州恩泽医疗中心(集团) 抗hla-g异构体分子hla-g5及hla-g6的单克隆抗体及其用途
WO2022129120A1 (en) 2020-12-17 2022-06-23 F. Hoffmann-La Roche Ag Anti-hla-g antibodies and use thereof
CN112794908A (zh) * 2020-12-31 2021-05-14 杭州冰湖生物科技有限公司 一种抗hla-g抗体的制备及分析方法
CN113278590A (zh) * 2021-04-23 2021-08-20 台州恩泽医疗中心(集团) 表达α1α2结构域缺失的HLA-G异构体标准蛋白的细胞株及其应用
GB202111905D0 (en) * 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
CN115925930B (zh) * 2021-11-04 2025-10-31 台州恩泽医疗中心(集团) 一种抗hla-g1、hla-g4及hla-g5异构体分子的单克隆抗体及其用途
CN114605543B (zh) * 2021-12-17 2023-11-07 台州恩泽医疗中心(集团) 一种抗hla-g异构体分子hla-g5及hla-g6的单克隆抗体及其用途
EP4473006A2 (en) 2022-02-04 2024-12-11 NKILT Therapeutics, Inc. Chimeric ilt receptor compositions and methods
JP2025514619A (ja) * 2022-03-25 2025-05-09 エイチケー イノ．エヌ コーポレーション Ｈｌａ－ｇ特異的抗体及びその用途
CN115819583A (zh) * 2022-03-31 2023-03-21 台州恩泽医疗中心(集团) 一种抗hla-g分子的单克隆抗体及其用途
CN116284387B (zh) * 2022-07-15 2025-10-03 台州恩泽医疗中心(集团) 一种抗hla-g2及hla-g6分子的单克隆抗体及用途
CN117448412A (zh) * 2022-07-26 2024-01-26 中山大学孙逸仙纪念医院 CD158d分子、其中和抗体，及应用
WO2024108568A1 (zh) * 2022-11-25 2024-05-30 深圳先进技术研究院 抗人类白细胞抗原-g纳米抗体及其制备方法与应用
CN119080938B (zh) * 2023-06-05 2025-06-24 东莞市朋志生物科技有限公司 抗25羟维生素d抗体、检测25羟维生素d的试剂和试剂盒
KR102793781B1 (ko) * 2023-10-12 2025-04-14 주식회사 아이엠바이오로직스 Hla-g에 특이적으로 결합하는 항체 및 이의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031604A1 (en) 1995-04-07 1996-10-10 The Regents Of The University Of California Antibodies for the detection of hla-g
WO2014072534A1 (en) * 2012-11-12 2014-05-15 Intelectys Antibodies and fragments thereof raised against the alpha-3 domain of hla-g protein, methods and means for their preparation, and uses thereof.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1312182C (zh) * 2004-10-26 2007-04-25 四川新创生物科技有限公司 抗hla－g的单克隆抗体及分泌它的杂交瘤细胞株、癌症诊断试剂盒及其应用
WO2008121894A2 (en) * 2007-03-30 2008-10-09 Escape Therapeutics, Inc. Endogenous expression of hla-g and/or hla-e by mesenchymal cells
EP2184070A1 (en) * 2008-11-07 2010-05-12 Hla-G Technologies HLA-G proteins and pharmaceutical uses thereof
EP2264067A1 (en) * 2009-06-18 2010-12-22 Hla-G Technologies HLA-G alpha 1 multimers and pharmaceutical uses thereof
CN101967191A (zh) * 2009-07-28 2011-02-09 广州天美生物技术有限公司 Hla-g抗体制备方法及其在医学中的应用
CN102086459A (zh) * 2009-12-08 2011-06-08 华中科技大学 一种融合蛋白免疫抑制剂及其制备方法和应用
US10800847B2 (en) 2012-01-11 2020-10-13 Dr. Mepur Ravindranath Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use
US20190119385A1 (en) 2015-03-27 2019-04-25 University Of Southern California Hla-g as a novel target for car t-cell immunotherapy
NZ788807A (en) 2016-06-03 2025-11-28 Invectys Anti hla-g specific antibodies
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031604A1 (en) 1995-04-07 1996-10-10 The Regents Of The University Of California Antibodies for the detection of hla-g
WO2014072534A1 (en) * 2012-11-12 2014-05-15 Intelectys Antibodies and fragments thereof raised against the alpha-3 domain of hla-g protein, methods and means for their preparation, and uses thereof.

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BENSUSSAN A ET AL: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 92, no. 22, 24 October 1995
SHIROISHI MITSUNORI ET AL: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 100, no. 15, 22 July 2003

Also Published As

Publication number Publication date
CN115286695A (zh) 2022-11-04
JP2022084670A (ja) 2022-06-07
US20190233520A1 (en) 2019-08-01
IL263266B2 (en) 2024-07-01
WO2017207775A1 (en) 2017-12-07
US20220056140A1 (en) 2022-02-24
CA3025681A1 (en) 2017-12-07
US11634494B2 (en) 2023-04-25
EP3464364A1 (en) 2019-04-10
US11111302B2 (en) 2021-09-07
US20220251216A1 (en) 2022-08-11
MX2018014979A (es) 2019-10-14
AU2017272875A1 (en) 2018-12-20
US11312774B2 (en) 2022-04-26
IL263266A (en) 2018-12-31
JP2019528038A (ja) 2019-10-10
US20210054081A1 (en) 2021-02-25
CN109563169A (zh) 2019-04-02
JP7034950B2 (ja) 2022-03-14
IL263266B1 (en) 2024-03-01
CN109563169B (zh) 2022-07-01
EA201892793A1 (ru) 2019-06-28
NZ788807A (en) 2025-11-28
NZ748929A (en) 2025-11-28
SG11201810149VA (en) 2018-12-28
BR112018074847A2 (pt) 2019-03-26
KR20190044589A (ko) 2019-04-30
AU2017272875B2 (en) 2023-10-19
SG10202107205VA (en) 2021-08-30
ZA201808332B (en) 2019-08-28
US20210309748A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
KR102465491B1 (ko) 항 hla-g 특이적 항체
US12234286B2 (en) Anti-TIGIT antibodies and their use as therapeutics and diagnostics
KR102372274B1 (ko) 세포독성 t-림프구-관련 단백질 4 (ctla-4)에 대한 신규의 단일클론 항체
JP2022130393A (ja) 抗ｃｔｌａ４－抗ｐｄ－１二機能性抗体、その医薬組成物および使用
KR102022734B1 (ko) 신규 조절제 및 용법
JP2022159548A (ja) ヒト化ｃｃケモカイン受容体４（ｃｃｒ４）抗体およびその使用法
KR20210143192A (ko) 변형된 Fc 단편, 이를 포함하는 항체 및 이의 응용
CN110462038A (zh) 抗gprc5d抗体和包含所述抗体的分子
KR20170128234A (ko) Ror1에 특이적인 항체 및 키메라 항원 수용체
RS52439B (sr) Humana antitela prema humanom delti sličnom ligandu 4
US20250361321A1 (en) Antibodies to mucin-16 and methods of use thereof
JP2025128164A (ja) 抗ｔｒｅｍ２抗体の使用方法
WO2021097800A1 (en) Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof
KR20180101483A (ko) 치료적 항-ｃｄ９ 항체
CN112625130A (zh) 抗-tigit抗体及使用之方法
JP7625516B2 (ja) Ｈｅｒ２ ｓ３１０ｆ特異的な抗原結合分子
JP2023530797A (ja) 部位特異的Ｎｏｔｃｈ活性化分子およびその使用
EA043548B1 (ru) Анти-hla-g специфические антитела
JP2022060048A (ja) 抗体及びその使用
HK40044258A (en) Multispecific antibodies and use thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000